Aurealis Therapeutics, a Swiss-Finnish clinical-stage synthetic biology company creating bacteria-based multi-factor cell and gene therapies for chronic wounds and cancer, is excited to share its recent feature in the well-known life science journal, Nordic Life Science News. The article titled “From Theory to Therapy: Gene Therapy” has shared remarkable insights from an interview with Laurent Décory, COO of Aurealis Therapeutics.
The article, written by Malin Otmani, dives into the powerful world of gene therapy offering a rich exploration of the current landscape, impact and results made in this field. In the interview, Laurent Décory highlights the importance and benefits that gene therapies bring to patients and the society as a whole. He also explains the mode-of-action of Aurealis Therapeutics’ bacterial cell and gene therapy platform and brings attention to the results that the company has currently achieved in the fields of chronic wounds and oncology.
“We are honored to be featured in Nordic Life Science News and share more about Aurealis Therapeutics technology platform as well as current operations with the life sciences community,” said Laurent Décory, COO of Aurealis Therapeutics. “We want to express our appreciation to Malin Otmani and Nordic Life Science News for this opportunity. Our commitment is to continue the development of gene therapies that positively impact the lives of patients and provide an effective option to currently unmet medical needs.”
About Aurealis Therapeutics
Aurealis Therapeutics AG is a Swiss-Finnish clinical-stage synthetic biology company creating bacteria-based multi-factor cell and gene therapies for chronic wounds and cancer. The company’s lead clinical assets are the first-in-class four-in-one cell and gene therapies AUP-16 for chronic wounds and AUP-55 for cancers. Aurealis therapies are based on proprietary technology involving genetically engineered Lactococcus Cremoris acting as millions of small immune-activating bioreactors producing multiple human therapeutic proteins (cytokines, growth factors, antibody fragments) to effectively and safely re-educate the distorted host immune microenvironment to a proper state.
For more information:
Laurent Décory, COO
Email: laurent@aurealistherapeutics.com
